[Federal Register Volume 77, Number 222 (Friday, November 16, 2012)]
[Notices]
[Page 68784]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2012-27895]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention


Prospective Grant of Exclusive License: Multiple-Valent 
Opsonophagocytic Assay Selection Panel Arrays

AGENCY: Centers for Disease Control and Prevention (CDC), Department of 
Health and Human Services (HHS).

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: This is a notice in accordance with 35 U.S.C. 209(e) and 37 
CFR 404.7(a)(1)(i) that the Technology Transfer Office, Centers for 
Disease Control and Prevention (CDC), Department of Health and Human 
Services (HHS), is thinking about giving a worldwide, exclusive license 
to practice the inventions listed in the patent referred to below to 
Flow Applications, Inc., having a place of business in Okawville, 
Illinois. The patent rights in these inventions have been assigned to 
the government of the United States of America. The patent to be 
licensed is:

    US Patent 7,642,068, entitled, ``Multiple-Valent 
Opsonophagocytic Assay Selection Panel Arrays and Uses Therefor'', 
issued 1/5/2010. CDC Technology ID No. I-035-04.

    Status: Patent Issued.
    Priority Date: 4/22/2005.
    Issue Date: 1/5/2010.
    The planned exclusive license will be royalty-bearing and will 
comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7.
    Technology: This technology utilizes a specific medium for the 
selection of up to 90 different Streptococcus pneumoniae serotypes 
following a viability opsonophagocytosis assay. This medium includes 
different antibiotics, growth factors for pneumococcus, and a 
colorimetric detection agent. These specific antibiotic panels can be 
preserved for later use in conjunction with a panel of selected 
pneumococcal strains that will allow for the measurement of functional 
antibodies elicited by pneumococcal vaccines.

DATES: Only written comments and/or applications for a license which 
are received by CDC on or before December 3, 2012 will be considered.

ADDRESSES: Requests for a copy of this patent, inquiries, comments, and 
other materials relating to the contemplated license should be directed 
to Donald Prather, J.D., Ph.D., Technology Licensing and Marketing 
Specialist, Technology Transfer Office, Centers for Disease Control and 
Prevention (CDC), 4770 Buford Highway, Mailstop K-79, Atlanta, GA 
30341, Telephone: (770) 488-8612; Facsimile: (770) 488-8615: Email: 
dwj5@cdc.gov.

SUPPLEMENTARY INFORMATION: Applications for a license filed in response 
to this notice will be treated as objections to giving the planned 
license.
    Comments and objections submitted in response to this notice will 
not be made available for public inspection, and, to the extent 
permitted by law, will not be released under the Freedom of Information 
Act, 5 U.S.C. 552.

    Dated: November 8, 2012.
J. Ronald Campbell,
Director, Division of Executive Secretariat Centers for Disease Control 
and Prevention.
[FR Doc. 2012-27895 Filed 11-15-12; 8:45 am]
BILLING CODE 4163-18-P